

*Medivir***Notice of Full Year and Fourth Quarter Financial Results
Conference Call****THURSDAY FEBRUARY 23, 2012****Conference Call at 14:00 (CET) / 13:00 (GMT) / 8:00 AM (EST)**

Medivir, the emerging research-based specialty pharmaceutical company focused on infectious diseases, will release its full year and fourth quarter financial results for the year ended 31st December 2011 on **Thursday, February 23, 2011**.

Medivir's senior management team will host an investor and analyst conference call at **14:00 (CET) / 13:00 (GMT) / 8:00 AM (EST)** to review the results and discuss the Group's business performance and activities.

CONFERENCE CALL

Dial in details: Sweden: +46 (0)8 505 204 24
UK: +44 (0)20 3003 2666
US: +1 866 966 5335

Please state that you would like to connect to the Medivir conference call on request.
You can also access the audio webcast and presentation via the Company's website www.medivir.com

For international Sell Side enquiries please contact:
Hollie Vile at M:Communications
Tel: +44 (0)20 7920 2354
Email : Hollie@mcomgroup.com

For international Buy Side enquiries please contact:
Devina Artley at Taylor Rafferty
Tel:+44 (0)20 7614 2900
Email : Medivir@taylor-rafferty.com

About Medivir

Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Tibotec Pharmaceuticals. In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, has been launched in the US and Europe. Xerese®/Xerclear®, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website: www.medivir.com